Anticoagulation strategies for venous Thromboembolism: Moving towards a Personalised approach

Thrombosis and Haemostasis

Volumn 114, Issue 4, 2015, Pages 660-669

  Black, Stephen A ^a   Cohen, Alexander T ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trials; Deep vein thrombosis; Oral anticoagulants; Pulmonary embolism; Venous thrombosis

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; BRAIN NATRIURETIC PEPTIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DABIGATRAN; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN; RIVAROXABAN; THROMBIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); MONOTHERAPY; NEOPLASM; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RENAL CLEARANCE; REVIEW; SEVERE RENAL IMPAIRMENT; VENOUS THROMBOEMBOLISM; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PULMONARY EMBOLISM; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PRECISION MEDICINE; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84943156172     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1028     Document Type: Review

References (65)

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-1846.
2. Heit JA, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med 2000; 160: 761-768.
3. Wan Y, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
4. Rose AJ, et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation results of the Veterans Affairs Study To Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011; 4: 22-29.
5. Schulman S, et al. RE-COVER Study Group. Dabigatran vs warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
6. Schulman S, et al. RE-MEDY Trial Investigators. RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
7. Schulman S, et al. Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764-772.
8. Agnelli G, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
9. Büller HR, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
10. Agnelli G, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
11. Agnelli G, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
12. Büller HR, et al. Hokusai-VTE Investigators. Edoxaban vs warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
13. Lassen MR, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
14. Eriksson BI, et al. Dabigatran etexilate vs enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
15. Eriksson BI, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
16. Eriksson BI, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
17. Kakkar AK, et al. Extended duration rivaroxaban vs short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
18. Turpie AG, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
19. Lassen MR, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
20. Fuji T, et al. A doseranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010; 8: 2458-2468.
21. Buller HR, et al. A dose ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-2247.
22. Buller H, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis: the Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
23. MacLean S, et al. American College of Chest Physicians. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e1S-23S.
24. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. Guidance.nice.org.uk/cg144. Accessed March 31, 2014.
25. Konstantinides S, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; Epub ahead of print.
26. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins vs adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; 9: CD001100.
27. Brandjes DP, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 19: 1485-1489.
28. Stein PD, et al. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 2010; 123: 426-431.
29. Heit JA, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
30. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122: 743-752.
31. Van Es J, et al. Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost 2013; 11: 679-685.
32. Kucher N, Goldhaber SZ. Cardiac biomarkers for riusk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-2194.
33. Schoepf UJ, et al. Right ventricular enlargement on chest computed tomography a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280.
34. Monreal M, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry. Am J Med 2006; 119: 1073-1079.
35. Stangler J, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
36. Poulsen BK, et al. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72: 1739-1753.
37. Product label for Pradaxa (dabigatran etexilate mesylate). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s0111b1.pdf. Accessed January 15, 2015.
38. Wang X, et al. Apixaban pharmaco-kinetics in subjects with end-stage renal disease on hemodialysis. Poster presented at: 2012 American College of Clinical Pharmacology Annual Meeting; September 23-25, 2012; San Diego, CA.
39. Hylek EM, et al. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACS) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
40. Prandoni P, et al. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-445.
41. Dietcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29: 247-258.
42. Heit JA. Predicting the risks of venous thromboembolism recurrence. Am J Hematol 2012; 87: s63-67.
43. Prandoni P, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
44. Louzada ML, et al. Efficacy of low-molecular-weight heparin vs vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123: 837-844.
45. Agnelli G, et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Eur Heart J 2014; 35 (Abstract Suppl.): 994.
46. Carrier M, et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SCC of the ISTH. J Thromb Haemost 2013; 11: 1760-1765.
47. Hutten BA, Prins MH. Duration of treatment with vitamin k antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; 1: CD001367.
48. Boutitie F, et al. Influence of preceding duration of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping therapy: analysis of individual participants’ data from seven trials. Br Med J 2011; 342: d3036.
49. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
50. Ageno W, et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2012; 11: 177-179.
51. Makris M, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160: 35-46.
52. Kaatz S, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-145.
53. Kaatz S, Crowther M. Reversal of target specific oral anticoagulants. J Thromb Thrombolysis 2013; 36: 195-202.
54. Makris M. Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: good enough for now? J Thromb Haemost 2014; 12: 1425-1427.
55. Levy JH, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466-1474.
56. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014; 111: 189-198.
57. Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
58. Schiele F, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
59. Raghavan N, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos, Biol Fate Chem 2009; 37: 74-81.
60. Wang L, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448-458.
61. Stangier J, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59.
62. Matsushima N, et al. Absolute bioavailability of edoxaban in healthy subjects. AAPS J 2011; 13: S2(Abstract).
63. Ogata K, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
64. Samama MM, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
65. Kubitza D, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.